178311-82-5Relevant academic research and scientific papers
Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "tail Switching" Strategy on a Piperazinyl Azetidine Skeleton
Chen, Zhen,Mori, Wakana,Deng, Xiaoyun,Cheng, Ran,Ogasawara, Daisuke,Zhang, Genwei,Schafroth, Michael A.,Dahl, Kenneth,Fu, Hualong,Hatori, Akiko,Shao, Tuo,Zhang, Yiding,Yamasaki, Tomoteru,Zhang, Xiaofei,Rong, Jian,Yu, Qingzhen,Hu, Kuan,Fujinaga, Masayuki,Xie, Lin,Kumata, Katsushi,Gou, Yuancheng,Chen, Jingjin,Gu, Shuyin,Bao, Liang,Wang, Lu,Collier, Thomas Lee,Vasdev, Neil,Shao, Yihan,Ma, Jun-An,Cravatt, Benjamin F.,Fowler, Christopher,Josephson, Lee,Zhang, Ming-Rong,Liang, Steven H.
supporting information, p. 3336 - 3353 (2019/03/29)
Monoacylglycerol lipase (MAGL) is a serine hydrolase that degrades 2-arachidonoylglycerol (2-AG) in the endocannabinoid system (eCB). Selective inhibition of MAGL has emerged as a potential therapeutic approach for the treatment of diverse pathological co
COMBINATION THERAPIES FOR TREATMENT OF CANCER
-
, (2016/04/09)
Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
COVALENT INHIBITORS OF KRAS G12C
-
, (2014/09/30)
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
-
Page/Page column 97, (2010/11/05)
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I), wherein Y, Z, R1, and s are defined herein.
Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists
-
, (2008/06/13)
Compounds of the formula (I): where X1, A, Ar1, X and R are as defined in the specification, and pharmaceutically-acceptable salts thereof, are new, and are useful as tachykinin inhibitors which act at the NK1, NK2and NK3receptors or a combination of two or more thereof.
